Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Announces Relevant Securities in Issue as Per the Irish Takeover Rules

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) has announced that, as of the close of business on July 28, 2021, its issued share capital, excluding treasury shares, consists of around 66.497 common stock shares with a par value of $0.0001 per share, as per the Irish Takeover Panel Act, 1997’s Rule 2.10, Takeover Rules 2013.

Xeris has 5.081 issued stock options 

The Nasdaq Global Select Market trades Xeris’ common stock under the name XERS. US98422L1070 is the International Securities Identification Number (ISIN) for Xeris common shares.

The company confirmed that there were around a 5.081million common stock shares purchase options (the Xeris Stock Options),  94,012 warrants, approximately 2.06 million Xeris restricted stock units, and a principal amount of $47.175 million of 5% Convertible Senior Notes due 2025 outstanding as of the close of business on July 28, 2021.

Each Stock Option permits the holder to purchase one Xeris common stock share at the corresponding exercise price when the option is exercised. Also, each Xeris Restricted Stock Unit permits the bearer to get one share of common stock upon vesting. Once exercised each Warrant grants the bearer to one Xeris common stock share. Up to 15.417 million Xeris common stock shares may be issued upon conversion of the Xeris Convertible Notes.

Xeris advancing various therapeutics 

The company is advancing a portfolio of solutions in several therapeutic categories, including its maiden commercial product, Gvoke in the United States, using a revolutionary technological platform that provides ready-to-use, room-temperature durable formulations of injection medicines. Its novel XeriSol and XeriJect formulation techs have the capability of offering benefits over traditional product formulations. Benefits include eliminating the need for reconstitution, allowing long-term, room-temperature durability, substantially minimizing injection volume, and eradicating intravenous (IV) infusion needs. In addition, new product formulations based on Xeris’ technology have been designed to be simpler to use by patients, carers, and physicians and to assist payers and the healthcare system save money.

Leave a Comment

Your email address will not be published.